AllergyTalk

AllergyTalk FIT Episode 2: I’ve Landed the Job–Now What?

Special Episode
ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to discuss advice on landing your first position. Continuing the conversation from Part 1, in this episode, our experts cover how to narrow down your choices, make sense of contracts and negotiations, decide whether to involve a contract lawyer, and plan a smooth transition into your next chapter.
Earn CME credit for listening to this episode! Free for College members!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to discloseKylie Jungles, MD: No relevant financial relationships with ineligible companies to discloseMelinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk FIT Episode 1: Navigating the Job Search

Special Episode
ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to share essential tips for fellows-in-training starting their job search. Learn how to choose the right practice setting, create a strategic job search plan, and interview with confidence.
Earn CME credit for listening to this episode! Free for College members!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to discloseKylie Jungles, MD: No relevant financial relationships with ineligible companies to discloseMelinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Understanding the FDA Warning on Cetirizine/Levocetirizine

Special Episode
On May 16, 2025, the FDA issued an alert regarding a rare but serious side effect of severe pruritus after discontinuing long-term use of cetirizine and levocetirizine. In this episode, we’ll discuss the background of this important announcement and what it means for our patients!
Michael S. Blaiss, MD, Clinical Professor of Pediatrics at the Medical College of Georgia and past-president and former Executive Medical Director of the American College of Allergy, Asthma, and Immunology. He has been a consultant for multiple companies manufacturing second generation antihistamines. Dr. Blaiss was joined by host Dr. Gerald Lee, MD, FACAAI.
Resources:
FDA Drug Safety Communication on Cetirizine and Levocetirizine
ACAAI Advice on Speaking Points Regarding FDA Alert
Previous articles describing this side effect:
Unbearable Pruritus After Withdrawal of (Levo)cetirizine
Pruritus after discontinuation of cetirizine
Make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 52 - Is Treatment Refractory Wheezing a Sign of a Silent Viral infection?

Dr. Sarah Spriet, DO, Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the January/February 2025 issue of AllergyWatch®.
Articles Reviewed:
A novel syndrome of silent rhinovirus-associated bronchoalveolitis in children with recurrent wheeze
Effects of moderate- versus vigorous-intensity exercise training on asthma outcomes in adults
Human Neutrophils Couple Nitric Oxide Production and Extracellular Trap Formation in Allergic Asthma
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: GenentechSarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 

Episode 51 - Does Eosinophil Depletion Improve Eosinophilic Esophagitis?

Dr. Iris Otani, MD, an associate professor of medicine at UCSF and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the November/December 2024 issue AllergyWatch®.
Articles Reviewed:
Frequencies and predictors of subcutaneous and intraosseous injection with 4 epinephrine autoinjector devices
Forecasting daily total pollen concentrations on a global scale
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: GenentechIris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 50 - Can Asthma Biologics Affect Vaccine Immunity?

Dr. Iris Otani, MD, an associate professor of medicine at UCSF and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the November/December 2024 issue AllergyWatch®.
Articles Reviewed:
Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial
Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study
Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: GenentechIris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 49 – The Mental Health Impact of Eczema and Food Allergies

Dr. Vivian Hernandez Trujillo, MD, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of AllergyWatch and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2024 issue AllergyWatch.
Articles Reviewed:
The mental health burden of food allergies: Insights from patients and their caregivers from the Food Allergy Research & Education (FARE) Patient Registry
Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders
Bronchoconstriction damages airway epithelia by crowding-induced excess cell extrusion
The speakers have the following disclosures:
Dr. Lee has been a speaker for NovartisDr. Fineman has nothing to discloseDr. Hernandez Trujillo:Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, TakedaConsultant: Pharming, KaleoSpeaker: CSL, Takeda, Kaleo
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 48 - Can Blood Transfusions Trigger Food Allergy?

Welcome to Season Three of Allergytalk!
Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 
For information about CME credit, head over to http://education.acaai.org/allergytalk
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
IgE to cross-reactive carbohydrate determinants (CCD) in childhood: Prevalence, risk factors, putative origins. 
Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food.
Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
 
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis
Dr. Fineman has nothing to disclose
Dr. Hernandez Trujillo:
Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda
Consultant/Speaker: Kaleo
Consultant: Allergy & Asthma Network, Pharming
Speaker: CSL, Takeda
 

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI
 
Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.
 
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Employ strategies for long-term prophylaxis.
References:
Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022
 
Speaker Disclosures:
Kristin C. Sokol, MD, MS, MPH, FACAAI
Advisor: Sanofi, Genentech, SELF/Conde Nast
 
Aleena Banerji, MD
Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda
Researcher: Astria, Ionis, Intellia
 
Jonathan A. Bernstein, MD, FACAAI
Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva
 
This podcast miniseries is supported by a grant from Takeda.

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 2 – Overcoming Barriers in HAE Treatment

Episode 2: Overcoming Barriers in HAE Treatment
 
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI
 
This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.
 
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Create effective treatment plans for their specific population (minority, rural, urban)
 
References:
Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022
 
Speaker Disclosures:
Kristin C. Sokol, MD, MS, MPH, FACAAI
Advisor: Sanofi, Genentech, SELF/Conde Nast
 
Jonathan A. Bernstein, MD, FACAAI
Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva
 
Timothy J. Craig, DO, FACAAI
Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda
Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda
Independent Contractor: Kalvista, Phavaris
Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda
Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda
 
This podcast miniseries is supported by a grant from Takeda.